ERBB2 and breast carcinoma: In addition to the downregulation of Src, dasatinib was shown to exhibit its effect on BC cell lines through decreasing the phosphorylation of EGFR, as dasatinib was able to induce apoptosis in breast cancer cells (MDA-MB-468, SKBR3, MDA-MB-453, and MDA-MB-231) overexpressing EGFR, HER-2, and HER-3.